MRI-Targeted Biopsy in Prostate Cancer Screening

Abstract

To the Editor: In the STHLM3-MRI trial, Eklund et al. (July 9 issue)¹ report that the percentage of men in whom clinically insignificant cancer was detected was lower with the use of magnetic resonance imaging (MRI)–targeted biopsy than with standard systematic biopsy, whereas the percentage of those who received a diagnosis of clinically significant cancer was higher with MRI-targeted biopsy. The authors acknowledge the lack of consensus in the definition of clinically significant cancer and, in line with previous studies, used a biopsy Gleason score of 7 or higher to define this end point (scores range from 6 to 10, . . .